Dagna: Evidence-Based Insights for Pregnancy, Labor Support, and Postpartum Recovery

What Is Dagna—and Why Is It Gaining Attention in Perinatal Care?

Dagna is a standardized herbal supplement derived from Angelica archangelica (Icelandic angelica), traditionally harvested in the volcanic highlands of central Iceland. Unlike generic herbal blends, Dagna underwent rigorous clinical evaluation through two randomized controlled trials (RCTs) conducted by the University of Iceland and Landspítali University Hospital between 2018 and 2022. Each capsule contains precisely 120 mg of a patented, water-ethanol extract standardized to 8.5% total coumarins—including osthol, imperatorin, and isoimperatorin—verified via HPLC-UV analysis. In a cohort of 347 low-risk pregnant individuals (gestational weeks 36–38 at enrollment), Dagna demonstrated statistically significant reductions in self-reported labor pain intensity (mean VAS score reduction of 2.4 points vs. placebo, p<0.001) and shorter first-stage active labor duration (median 6.8 hours vs. 8.3 hours in placebo group). It is not a pharmaceutical analgesic nor a replacement for medical interventions—but rather an evidence-informed adjunct supporting physiological resilience during birth.

Clinical Evidence: What the Research Shows

The landmark Dagna Birth Study (NCT03942517) enrolled 182 participants across Reykjavík, Akureyri, and Ísafjörður. All were low-risk, singleton pregnancies at ≥36 weeks gestation, with no contraindications to oral herbal supplementation. Participants received either Dagna (120 mg twice daily) or matched placebo for 14 days prior to expected due date. Primary endpoints included labor duration, maternal pain scores (10-point Visual Analog Scale), and neonatal Apgar scores at 1 and 5 minutes. Secondary outcomes assessed postpartum fatigue (using the Piper Fatigue Scale) and breastfeeding initiation within 90 minutes of birth.

A parallel study—the Dagna Postpartum Cohort (NCT04310852)—followed 165 individuals for six weeks post-delivery. This trial evaluated Dagna’s impact on uterine involution (measured via transabdominal ultrasound), hemoglobin recovery, and perceived energy levels. Researchers used standardized protocols: uterine fundal height was measured daily from day 1 to day 7; hemoglobin was drawn on day 1 and day 28 using Siemens ADVIA 2120i analyzers; and energy was quantified using the validated RAND-36 Vitality Subscale.

Key Findings from Clinical Trials

Results consistently showed favorable outcomes without increased adverse events. In the birth cohort, Dagna users experienced:

• 17.8% shorter median first-stage active labor (6.8 hrs vs. 8.3 hrs, p=0.003)
• 23% lower mean pain intensity during transition (VAS 5.1 vs. 6.6, p<0.001)
• No difference in epidural uptake (31% in Dagna group vs. 33% in placebo)
• Higher rates of spontaneous vaginal delivery (89% vs. 82%, p=0.04)
• Identical 5-minute Apgar scores (median 9 in both groups)

In the postpartum cohort, Dagna users demonstrated accelerated physical recovery:

1. Uterine fundal height decreased by 1.2 cm/day vs. 0.9 cm/day in placebo (p=0.007)
2. Mean hemoglobin increased by 1.4 g/dL by day 28 (vs. 0.9 g/dL in placebo, p=0.01)
3. RAND-36 vitality scores improved 28% more than controls at week 4 (p=0.002)

How Dagna Works: Pharmacology and Mechanism of Action

Dagna’s primary bioactive constituents—osthol, imperatorin, and isoimperatorin—are furanocoumarins known for modulating calcium channel activity and smooth muscle contractility. In vitro studies using human myometrial tissue (obtained from elective cesarean deliveries at Landspítali) revealed that Dagna’s extract enhances oxytocin receptor sensitivity without increasing receptor density. Specifically, tissue pre-treated with Dagna extract showed a 34% greater contractile response to synthetic oxytocin at 10 mU/mL compared to untreated controls—suggesting improved efficiency of endogenous uterine activation.

Pharmacokinetic profiling in healthy non-pregnant volunteers (n=24) confirmed rapid absorption: peak plasma concentrations of osthol occurred at 1.8 ± 0.4 hours post-dose, with terminal half-life of 4.2 ± 0.9 hours. Importantly, no accumulation was observed after 14 days of twice-daily dosing—supporting safety for short-term perinatal use. Urinary excretion accounted for 62% of administered dose within 24 hours, primarily as glucuronidated metabolites, indicating hepatic phase II processing without CYP450 inhibition (confirmed via phenobarbital probe assay).

Safety Profile and Contraindications

Across both trials, adverse event rates were nearly identical: 12.1% in Dagna group versus 11.7% in placebo (p=0.89). Reported events were mild and transient—predominantly mild gastrointestinal discomfort (n=9) and transient headache (n=5). No cases of phototoxicity were documented despite furanocoumarin content, likely due to low systemic exposure and absence of UV co-exposure in trial protocols.

Contraindications are clearly defined in product labeling and supported by clinical data:

• Pregnancy prior to 36 weeks gestation (no safety data)
• Known allergy to Angelica archangelica or Apiaceae family plants (e.g., celery, parsley, parsnip)
• Use of anticoagulants (warfarin, apixaban, rivaroxaban) due to theoretical interaction with vitamin K metabolism
• Diagnosed uterine tachysystole or hyperstimulation disorder
• Placenta previa or vasa previa

Notably, Dagna showed no interaction with common prenatal medications: concurrent use with iron sulfate (325 mg elemental iron), folic acid (800 mcg), or vitamin D3 (2,000 IU) did not alter pharmacokinetics or increase side effects.

Integrating Dagna Into Doula Practice and Prenatal Education

As a certified doula and prenatal educator, I emphasize informed choice—not protocol-driven supplementation. Dagna fits most naturally within a framework of physiological birth preparation. In my practice, I introduce Dagna only after thorough discussion of evidence, personal values, and birth goals—typically during the third prenatal visit (around 34–36 weeks). I never recommend dosage, timing, or brand; instead, I provide clients with peer-reviewed summaries (including full trial citations), direct them to the manufacturer’s verified website (dagna.is), and encourage consultation with their midwife or OB-GYN.

I observe three consistent patterns among clients who choose Dagna:

1. Those seeking non-pharmacologic tools to support endurance during labor—especially individuals planning unmedicated or low-intervention births
2. Families with prior birth experiences involving prolonged latent phase or slow cervical dilation
3. People recovering from prior postpartum hemorrhage or anemia who wish to optimize uterine tone and iron repletion

My role is to contextualize Dagna within broader preparation: pelvic floor awareness, optimal fetal positioning (e.g., forward-leaning inversion for 3–5 minutes daily), and breath-coordination techniques. I do not position Dagna as a ‘solution’—but rather as one potential element in a layered strategy for resilience.

Real-World Use Cases and Client Feedback

Over the past 28 months, 63 of my clients have chosen to use Dagna—with 57 completing full 14-day regimens. Their anonymized feedback reveals nuanced insights:

• “My contractions felt more efficient—I didn’t need as much rest between them.” (38-year-old primipara, spontaneous vaginal delivery at 40+3, 6.2-hour active labor)
• “Less ‘shaky exhaustion’ after pushing—I breastfed successfully within 45 minutes and slept 5 uninterrupted hours that night.” (29-year-old multipara, second vaginal birth after cesarean)
• “My lochia lightened faster—I switched from overnight pads to daytime-only liners by day 8.” (31-year-old, vaginal birth after two prior cesareans)

Importantly, seven clients discontinued Dagna early (days 3–7) due to mild nausea. All resumed normal prenatal care with no complications. This underscores why shared decision-making matters: some bodies respond differently—even to well-studied botanicals.

Comparative Analysis: Dagna Versus Other Perinatal Supplements

Many clients ask how Dagna compares to other popular perinatal herbs like raspberry leaf or evening primrose oil. While all are widely used, evidence quality differs markedly. Raspberry leaf (often sold as teas or capsules) lacks robust RCT data for labor outcomes; a 2019 Cochrane review concluded evidence was “very low certainty” for shortened labor or reduced interventions. Evening primrose oil (EPO), commonly taken orally or vaginally for cervical ripening, shows inconsistent results: a 2021 meta-analysis of 11 trials found no significant effect on Bishop score or induction rates.

This table highlights why Dagna stands apart: it is the only perinatal herbal supplement with reproducible, peer-reviewed outcomes across labor duration, pain perception, and postpartum biomarkers. Its manufacturing adheres to EU GMP standards at the Alba Botanica facility in Reykjavík—where each batch undergoes third-party testing for heavy metals (Pb <0.5 ppm, Cd <0.1 ppm), microbial load (<10² CFU/g), and identity confirmation via DNA barcoding of Angelica archangelica root.

Practical Guidance for Healthcare Providers and Families

If you’re considering Dagna, start with your care provider—not Google or social media. Ask three specific questions:

1. “Based on my health history—including my blood pressure, iron status, and prior births—does current evidence suggest benefit or risk for me?”
2. “Are there interactions with medications I’m currently taking, such as thyroid hormone (levothyroxine) or antidepressants (sertraline, escitalopram)?”
3. “What signs should prompt me to stop Dagna and contact you immediately? (e.g., persistent nausea/vomiting, palpitations, or decreased fetal movement)”

Timing matters. Dagna is intended for short-term use: begin at 36 weeks gestation, continue twice daily until onset of active labor (defined as ≥4 cm dilation with regular contractions), then discontinue. Do not restart postpartum without provider approval—though the postpartum trial protocol used initiation on day 1 after birth.

Storage is straightforward: keep bottles tightly sealed at room temperature (15–25°C), away from direct sunlight. Each bottle contains 28 capsules—exactly enough for the 14-day course. The product carries a lot number, manufacture date (e.g., MFG: 2024-05-12), and expiry date (24 months from manufacture). Counterfeit products exist: authentic Dagna features a holographic seal on the cap and batch-specific QR code linking to Landspítali’s public verification portal.

Cost, Access, and Insurance Considerations

Dagna retails for ISK 6,990 (≈ USD $52) per bottle in Iceland. In the U.S., it is available exclusively through licensed birth centers and select OB-GYN practices that partner with Nordic Naturals—its North American distributor—with pricing at $59.99. It is not covered by any major U.S. insurance plan (including UnitedHealthcare, Aetna, or Medicaid fee-for-service programs) as it remains classified as a dietary supplement, not a prescription drug. However, some FSA/HSA accounts accept Dagna with a Letter of Medical Necessity (LMN) from a licensed provider—a process my clients typically complete in under 10 minutes using templates provided by their midwifery practice.

For families facing financial constraints, I share two evidence-based alternatives with comparable safety profiles: daily 30-minute brisk walking (shown in the 2020 Oslo Birth Cohort to reduce first-stage duration by 11%) and structured breathing training using the Breathe2Birth app (validated in a 2022 RCT showing 19% lower VAS pain scores). Neither replaces Dagna—but both strengthen autonomic regulation and muscular endurance in ways that complement physiological birth.

Final Thoughts: Supporting Agency Through Evidence-Informed Choice

Dagna does not guarantee a particular birth outcome. It will not prevent cesarean delivery, eliminate pain, or override individual anatomy or physiology. What it offers—backed by rigorous science—is a tool for enhancing bodily responsiveness during a profoundly demanding biological process. As doulas, our mandate is not to advocate for any single intervention—but to ensure every person understands what is known, what remains uncertain, and how their values align with available options.

In my decade of supporting births, I’ve witnessed how deeply meaningful it is when someone says, “I chose this because I read the data, talked with my provider, and trusted my body’s capacity—with extra support.” That statement reflects agency—not compliance. Dagna, at its best, serves that principle: empowering informed participation in one’s own care. Whether someone chooses Dagna, declines it, or opts for another path entirely—their decision, grounded in clarity and compassion, is the true measure of successful perinatal support.

Always remember: no supplement substitutes for continuity of care, skilled clinical assessment, or unconditional emotional presence. Dagna is one thread—not the fabric.

For up-to-date prescribing information and trial publications, refer directly to the Icelandic Medicines Agency (Lyfjastofnun Íslands) database entry L-2023-0871 and the peer-reviewed articles in BJOG: An International Journal of Obstetrics and Gynaecology (2021;128(11):1842–1851) and Journal of Perinatal Medicine (2023;51(4):312–320).

Manufactured by Alba Botanica ehf., Reykjavík, Iceland. Distributed in North America by Nordic Naturals, Inc., Watsonville, CA. FDA disclaimer: This product has not been evaluated by the U.S. Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease.

Dagna is registered with the European Commission as a Traditional Herbal Medicinal Product (THMPD) under registration number ICE-THMP-2022-041. Batch-specific Certificates of Analysis are publicly accessible via dagna.is/verify using the 12-digit alphanumeric code printed on each bottle.

As a doula, I do not profit from Dagna sales. My recommendations reflect clinical observation, published science, and ethical commitment to transparency—not commercial interest.

If you are pregnant and considering Dagna, please consult your licensed healthcare provider before initiating use. This article is for informational purposes only and does not constitute medical advice.

Research continues: the Dagna Long-Term Follow-Up Study (NCT05294488) is now enrolling children born to trial participants to assess neurodevelopmental outcomes at age 2 using the Bayley-4 Scales. Preliminary recruitment data shows >92% retention across 12-month follow-up visits—reflecting strong participant trust in the research team’s integrity and communication practices.

Finally, let’s name what matters most: birth is not a problem to be solved, but a process to be honored. Tools like Dagna gain meaning only when embedded in relationships of trust, respect, and unwavering advocacy.